Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat Mesylate vs Heparin in Sepsis-Associated AKI
NCT06375616Phase 4Not yet recruiting
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of Nafabelltan in sepsis-associated acute kidney injury (S-AKI). Primary endpoint: Platelet decline rate at 7 days. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
Nafabelltan
03
Conditions
sepsis-associated acute kidney injury (S-AKI)
Beyond the preview
Go deeper on NCT06375616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06375616.